Skanska developed 150 Second St., which was completed this past December.

CAMBRIDGE, MA-Foundation Medicine Inc. has signed on as the anchor tenant for 150 Second St., a three-story office and lab building here developed by Skanska USA Commercial Development Inc. The tenant, which uses genomic analysis to help doctors identify targeted cancer treatments, expects to move into 61,591 square feet at 150 Second in September.

The site will house Foundation Medicine’s clinical laboratory as well as its research laboratory and commercial offices. Completed this past December, 150 Second represents Skanska’s first commercial development in Cambridge, among the Boston area’s leading biotechnology centers. Skanska acquired the property in November of 2010 and self-financed 100% of the development costs.

“The demand we are seeing for highly sustainable office and lab space in Kendall Square is a strong indicator that Cambridge will continue to attract the world’s leading biotechnology and life science companies, such as Foundation Medicine, and we look forward to witnessing the progress they will make in advancing cancer research in our building,” says Shawn Hurley, EVP and regional manager of Skanska USA Commercial Development in Boston, in a release. Jones Lang LaSalle represented Skanska USA, while Richards Barry Joyce & Partners represented Foundation Medicine.

This past December, Skanska USA announced that it had acquired Parcel L1 of Seaport Square in Boston’s Seaport District from MS Boston Seaport, LLC. It plans to develop a 455,000-square-foot commercial building with ground floor retail. LEED Gold or higher certification is the target. 

In March 2012, Skanska and partner Twining Properties said they had acquired Block K of Seaport Square and would develop Watermark Seaport, a planned residential tower with more than 300 apartments and 25,000 square feet of retail space targeting LEED Gold certification. Skanska also purchased the site at 1350 Boylston St. in Boston.